Tirzepatide for type 2 diabetes

作者
Sarah L. Anderson,Joel C. Marrs
出处
期刊:Drugs in context [BioExcel Publishing Ltd]
卷期号:12: 1-8 被引量:16
标识
DOI:10.7573/dic.2023-6-1
摘要

One in ten adults worldwide is living with diabetes, with 95% having type 2 diabetes (T2D).Sustained glycaemic control in people with T2D is difficult to achieve despite recent advances in T2D management with the advent of glucagon-like peptide 1 receptor agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGL-T2i).Tirzepatide represents a first-in-class agent as a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP1RA to be approved in the USA and Europe for the treatment of T2D.This narrative review intends to list and discuss the glycaemic efficacy, key safety and weight loss outcomes related to the treatment of T2D with tirzepatide.Tirzepatide has been evaluated in five published clinical trials (n=6278) within the SURPASS clinical trial programme, with a focus on glycaemic control and weight loss.These trials have demonstrated significant improvements in glycosylated haemoglobin (-1.24% to -2.11% versus placebo and -0.6% to -1.14% versus active comparator) and weight (up to 15.5 kg versus placebo or active comparator) in patients with T2D.Notably, tirzepatide exhibited superior glycaemic control and weight loss when compared directly with a GLP1RA.Adverse events with the use of tirzepatide are similar to other approved GLP1RA and are predominantly gastrointestinal (nausea, vomiting).The tirzepatide cardiovascular outcomes trial (SURPASS-CVOT) is in progress and is expected to be completed in the fall of 2024.Tirzepatide represents an attractive new option and first-in-class agent for the treatment of T2D in people unable to achieve their glycaemic or weight management goals.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
赵保钢发布了新的文献求助10
刚刚
emy发布了新的文献求助10
1秒前
1秒前
ychope完成签到,获得积分10
1秒前
anyanjiao发布了新的文献求助50
2秒前
盈虚者发布了新的文献求助10
3秒前
3秒前
null的应助被666采纳,获得10
3秒前
结实初兰完成签到 ,获得积分10
3秒前
Anna完成签到,获得积分20
4秒前
4秒前
aaa发布了新的文献求助30
6秒前
科研通AI6.4的应助被decade采纳,获得10
8秒前
白玄发布了新的文献求助10
8秒前
8秒前
9秒前
9秒前
张倾情发布了新的文献求助30
10秒前
10秒前
HJW完成签到,获得积分10
10秒前
11秒前
last123完成签到,获得积分10
12秒前
水水完成签到,获得积分10
12秒前
HJW发布了新的文献求助10
13秒前
朝颜发布了新的文献求助10
13秒前
青苹果蛋子完成签到 ,获得积分10
14秒前
土豆饼完成签到 ,获得积分10
14秒前
Ava的应助被Ting采纳,获得10
15秒前
15秒前
wenli发布了新的文献求助10
15秒前
16秒前
大猫完成签到 ,获得积分10
17秒前
www关注了科研通微信公众号
19秒前
李爱国的应助被感动的易真采纳,获得10
19秒前
陈00完成签到,获得积分10
20秒前
一块麻糖发布了新的文献求助10
20秒前
21秒前
要减肥听云完成签到,获得积分10
21秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158056
求助须知:如何正确求助?哪些是违规求助? 9553944
关于积分的说明 21716733
捐赠科研通 7747388
什么是DOI,文献DOI怎么找? 3426934
关于科研通互助平台的介绍 2551676
邀请新用户注册赠送积分活动 2471038